A 3-month, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a highly optimized, capacitively coupled, pulsed electrical stimulator in patients with osteoarthritis of the knee  by Garland, D. et al.
OsteoArthritis and Cartilage (2007) 15, 630e637
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2007.01.004A 3-month, randomized, double-blind, placebo-controlled study to
evaluate the safety and efﬁcacy of a highly optimized, capacitively
coupled, pulsed electrical stimulator in patients with
osteoarthritis of the knee1
D. Garland M.D., Directory, P. Holt M.D., Assistant Professor of Medicinez,
J. Timothy Harrington M.D., Associate Professor of Medicinex*a,
J. Caldwell M.D., Medical Affairsk, T. Zizic M.D., Associate Professor of Medicineza and
J. Cholewczynski B.S., Independent Clinical Statistician
yDivision of Neurotrauma, Rancho Los Amigos Medical Center, USA
z Johns Hopkins School of Medicine, Baltimore, MD, USA
xUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, USA
kBioniCare Medical Technologies, Inc., USA
Summary
Objective: To investigate the efﬁcacy and safety of a capacitively coupled, pulsed electrical stimulation device in treating knee osteoarthritis
(OA).
Design: Fifty-eight outpatients with moderate to severe OA of the knee entered a 3-month, double-blind, placebo-controlled trial, using either
an active or placebo device at home for 6 to 14 h/day. Outcome measures included a patient global evaluation, a patient report of knee pain
severity, and the Western Ontario and McMaster Universities (WOMAC) questionnaire.
Results: Active treatment provided superior outcomes between baseline and 3-month follow-up measurements: 50.6% greater improvement
than placebo in patient global (P¼ 0.03), 31.2% in patient pain (P¼ 0.04), 25.1% in WOMAC stiffness (P¼ 0.03), 29.5% in WOMAC function
(P¼ 0.01), 19.9% in WOMAC pain (P¼ 0.11), and 27% in total WOMAC (P¼ 0.01). The percent of patients who improved by more than 50%
was 38.5 active vs 5.3 placebo in patient global (P¼ 0.01), 43.6 vs 15.8 in patient pain (P¼ 0.04), 38.5 vs 10.5 in WOMAC pain (P¼ 0.03),
28.2 vs 5.3 in WOMAC stiffness (P¼ 0.08), 23.1 vs 5.3 in WOMAC function (P¼ 0.14), and 23.1 vs 5.3 in total WOMAC (P¼ 0.14).
Twenty-one percent of placebo and 18% of actively treated patients developed a transient rash at the electrode sites. No other adverse device
effects were reported.
Conclusion: A highly optimized, capacitively coupled, pulsed electrical stimulus device signiﬁcantly improved symptoms and function in knee
OA without causing any serious side effects.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Knee osteoarthritis, Pulsed electrical stimulation treatment.
International
Cartilage
Repair
SocietyIntroduction
Osteoarthritis (OA) of the knee is a degenerative disorder,
usually progressive, that results from excessive catabolism
and inadequate production of cartilage matrix1e4. The con-
sequences of this condition are degeneration in underlying
bone, inﬂammatory responses in the adjacent synovium,
and deterioration of other soft tissue structures within
the joint. No therapies exist currently that can reverse this
process. Nonoperative treatment of knee OA has chan-
ged very slightly over the past 40 years. Nonsteroidal
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Received 19 July 2006; revision accepted 2 January 2007.63anti-inﬂammatory drugs (NSAIDs) and analgesics relieve
pain and help knee OA patients function better, but many
patients fail or do not tolerate these medications. Hyalur-
onans work in patients with milder OA of the knee5. The
role of neutraceuticals such as glucosamine and chondroitin
sulfate remains controversial. An National Institutes of
Health (NIH)-sponsored trial of glucosamine and/or chon-
droitin sulfate in knee OA patients failed to show a therapeu-
tic effect of these agents6. The withdrawal of Cox II speciﬁc
NSAIDs rofecoxib and valdecoxib from the market has
diminished the number of available nonsurgical therapeutic
options. New therapies are needed.
Pulsed electrical stimulation (PES) provides such a new
therapy for knee OA, and possibly for other joint diseases
as well. An initial, 1-month (78 patients) randomized, dou-
ble-blind, placebo-controlled trial showed that a prototype
device for delivering an optimized PES signal to the knee
tissues improved symptomatic knee OA patients’ pain and
symptoms, physician global evaluation and patient assess-
ment of knee function7. The same device enabled 62% of0
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have total knee arthroplasty (TKA) to defer this surgery for 4
or more years, in contrast to 7% of a comparator group8,9.
An Food and Drug Administration (FDA) cleared, commer-
cially available version of this device (BioniCare Medical
Technologies, Inc., Model BIO-1000) has provided similar
relief of symptoms and improved patient and physician
global evaluations in 75% of an additional 288 patients
monitored in a phase IV study10.
The speciﬁc characteristics of this optimized PES signal
were derived from more than 20 years of research that
has explored homeostatic electrical signaling in articular
cartilage, the loss of signaling in OA, and the regenerative
effect of exogenous PES in animal models of cartilage in-
jury11e22. Its precise modes of action in human knee OA
have yet to be determined, but in vitro signaling of articular
cartilage explants has shown increased messenger RNA
transcription of genes that promote synthesis of chon-
drocyte Type II collagen and aggrecan, and suppression
of matrix metalloproteinases and interleukin-121,22. This
PES is analogous to bone stimulator therapy for fracture
nonunion23, and is not related to the mechanism of action
or clinical effects of transcutaneous electrical nerve stimula-
tion devices (TENS)24.
The present 3-month double-blind controlled study was
designed to conﬁrm and extend the previous observations
of clinical effectiveness of the BIO-1000 device in patients
with knee OA.
Materials and methods
STUDY POPULATION
Patients with moderate to severe knee OA were offered
study participation during regular ofﬁce visits in two orthope-
dic surgery and one rheumatology practices beginning in
December 2004 and ending in July 2005. No advertising
was done. Moderate to severe disease was deﬁned as per-
sistence of pain on NSAID and/or analgesic therapy and the
presence of KellgreneLawrence Grade 3 or 4 changes on
standing, weight bearing, semiﬂexed X-ray views of the
knees25,26. Patients with knee instability and/or valgus or
varus deformities of >20 were excluded.
A total of 103 patients signed informed consent forms.
Three patients withdrew prior to randomization due to un-
willingness to keep the appointments (one patient) or to
use the device as prescribed (two patients). Patients en-
tered at each site were separately randomized as described
below under Design and Randomization. All 42 subjects en-
tered by one orthopedic practice were subsequently omitted
because many were provided other, often undocumented,
new treatments during the study in violation of the protocol.
The 58 patients from the two remaining practices are in-
cluded in the analysis.
Other inclusion criteria included age 18 years or greater,
the intellectual ability to understand and sign an informed
consent and complete the study questionnaire, and willing-
ness to maintain stable doses of analgesics and NSAIDs for
1 month prior to study entry and during the 3-month double-
blind period. Other exclusion criteria were pregnancy,
breastfeeding, intention to become pregnant, infectious ar-
thritis, cardiac pacemakers or other implantable electronic
devices, a diagnosis of gout, recurrent inﬂammatory epi-
sodes of pseudogout, malignancy (other than basal cell car-
cinoma) in the prior 3 years, inﬂammatory arthritis such as
rheumatoid arthritis, psoriatic arthritis, Reiter’s syndrome,
hemochromatosis, inﬂammatory bowel disease, ankylosingspondylitis, other collagen vascular disease, Paget’s dis-
ease adjacent to the treated knee, signiﬁcant instability of
the treated knee as determined by the investigator, a history
of drug or alcohol abuse within the past 2 years, morbid
obesity (deﬁned as a body mass index (BMI) greater than
45), involvement in litigation or Workers’ Compensation, in-
tra-articular injection of the target joint within the past
month, previous arthroplasty of the treated knee, and ar-
throscopy in the treated knee within the past 6 months.
DESIGN
This was a 12-week, 2:1 active to placebo, randomized,
double-blind trial. The 2:1 ratio was chosen to encourage pa-
tient compliance. After signing the informed consent, patients
completed two sets of questionnaires, underwent a physical
examination, and received education as to device use at
two separate baseline visits 1 week apart. Standing, weight
bearing, semiﬂexed X-rays of the knees were also obtai-
ned25. Stable NSAID and/or analgesic use was maintained
1 month prior to and throughout the study rather than being
withdrawn to produce a disease ﬂare.
Subjects’ adherence to treatments, including the study
device and baseline NSAID and/or analgesic use, was
monitored by weekly phone calls from a contract research
organization and during 3 monthly follow-up visits with the
investigator, at which time examination and questionnaires
were also repeated. Hours of use were monitored by a timer
within the device, and were recorded during both phone
calls and visits. NSAID and analgesic use and device volt-
age settings were further conﬁrmed by daily diaries.
DEVICE USED
The PES study device consisted of a knee garment with
ﬂexible, embedded electrodes and a small battery-operated
generator that produced a 100-Hz, negative pulsed signal
(Fig. 1). It weighs 8 ounces. Patients were asked to wear
the device for 6 h or more each day, usually at night.
They ﬁrst applied a conducting gel to each electrode, then
positioned the garment with the negative electrode on the
skin over the patella and the positive return electrode over
the anterior distal thigh. They then turned on the device, in-
creased the signal amplitude to between 0 and 12 V by ro-
tating a dial until a tingling sensation was felt over the knee
or thigh, and then reducing the amplitude until this sensa-
tion disappeared. Thus active treatment remained imper-
ceptible and indistinguishable from placebo. The placebo
devices shut off after the amplitude was reduced, and
further adjustments required all devices to be restarted.
All active and placebo devices contain a timer that records
the cumulative hours when the device is in use. This PES
device is manufactured and sold by BioniCare Medical
Technologies, Inc., Sparks, Maryland.
OUTCOME MEASURES
Primary outcome measures were (1) the percent change
from baseline on a 0e100 visual analog scale (VAS) mea-
suring patient global evaluation of arthritis symptoms in the
treated knee (Question: Considering all the ways your ar-
thritis condition affects you, how are you doing today?),
(2) the percent change from baseline on a 0e100 VAS mea-
suring pain and other symptoms in the treated knee (Ques-
tion: Considering your pain and symptoms in your study
joint how are you doing today?), and (3) percent changes
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versities (WOMAC) pain (0e500), stiffness (0e200), and
function (0e850) subscales as measured on 100 mm
VASs. Secondary outcomes were the percent of patients
that experienced 50% improvement in the patient global
evaluation, pain and symptoms in the treated knee, and in
the three WOMAC outcome scale measures. The occur-
rence of rashes and other adverse device effects was soli-
cited and recorded at each visit.
STATISTICAL METHODS
Randomization
Each placebo and active device was assigned a unique
number. Each study site was provided both types of devices
in a ratio of two active to one placebo. A master random
number chart was generated and maintained by an inde-
pendent observer who had no interaction with the sponsors,
primary investigators or patients. As patients signed in-
formed consents they were assigned a device number seri-
ally. The number coincided with active or placebo units
according to the dictates of the random number table. The
clinical investigators had no inﬂuence on the assignment
of any speciﬁc patient to an active or placebo device. The
blind has never been revealed to any of the authors except
the statistician.
Baseline characteristics
Baseline values were analyzed by comparing means for
each treatment group for continuous variables such as
age, VAS or WOMAC outcome scale measurements, or
comparing patient counts for each treatment group for dis-
crete variables such as gender. Outcome measures for
the two baseline visits were averaged to provide each
Fig. 1. The PES study device consisted of an optional waistband,
a small battery-operated signal generator that produced a
100-Hz, negative pulsed signal, and a knee garment with ﬂexible,
embedded electrodes.subject’s baseline values. Statistical methods used in anal-
ysis were the t test for continuous variables or the Fisher’s
exact test for discrete variables.
Outcome measures
Percent changes from baseline to the ﬁnal visit on the
VAS and WOMAC scale were calculated as follows:
ðBaseline averagemonth three scoreÞ  100
Baseline average
Fisher’s exact test was used to compare gender, percent of
patients using assistive devices, need for TKA and 50%
responses in efﬁcacy outcomes at the ﬁnal visit between
active- and placebo-treated patients. Student’s t test was
used to compare percent changes in outcome measures
between the baseline and ﬁnal visits. Student’s t test was
also used to compare differences between treatments for
age, BMIs and years diagnosed.
Distribution of KellgreneLawrence scores between
groups was compared using the c2 test. SAS software, ver-
sion 9 was used to perform the statistical analysis.
Missing values
Two patients, one placebo and one active device treated,
discontinued study participation before the second month
follow-up visit. In both cases the missing outcomes at 3
months were imputed by last observation carried forward
(LOCF).
Data analysis
A contract research organization monitored the study,
and an independent statistician examined and statistically
evaluated the data results. The investigators did not see
the original data sets.
INSTITUTIONAL REVIEW BOARD APPROVAL
The Independent Investigational Review Board approved
the study.
EXPLORATORY ANALYSES REQUESTED DURING REVIEW
Total WOMAC scores were not a deﬁned outcome in the
protocol, but are shown in Tables II(a)e(d). The number of
patients in the active and placebo groups showing 50% im-
provement in one to six of the primary measures and total
WOMAC were also tabulated.
Results
PATIENT POPULATION BASELINE CHARACTERISTICS
Fifty-eight subjects were randomized to therapy. Tables
I(a) and (b) show their baseline demographics, use of med-
icines and assistive devices, whether treating physicians
considered them to be a candidate for TKA, and their base-
line disease severity measures. Subjects in each treatment
group were equivalent as to age, sex, BMI, baseline antiar-
thritic medical therapy and KellgreneLawrence X-ray score.
Those in the active group showed more severe patient
global evaluation scores (P¼ 0.04), but otherwise disease
severity was comparable. No explanation for this disparity
other than chance is apparent. The patients from rheuma-
tology and orthopedic practices were similar in both
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Baseline characteristics by treatment group. No statistically significant differences were present between active- and placebo-treated patients
Characteristic Active (N¼ 39) Placebo (N¼ 19) Total (N¼ 58)
Gender
Male, no. (%) 12 (30.8) 8 (42.1) 20 (34.5)
Female, no. (%) 27 (69.2) 11 (57.9) 38 (65.5)
Age, years (standard deviation) 64.3 (10.2) 69.9 (11.4) 66.1 (10.9)
Medication requirements
Analgesics alone (%) 28.2 26.3
NSAIDs alone (%) 59.0 47.4
AnalgesicsþNSAIDs (%) 12.8 26.3
Years diagnosed, mean (range) 9.0 (0.8e44.0) 7.2 (0.2e20.0) 8.4 (0.2e44)
BMI, mean (range) 31.3 (20e43) 30.2 (22e41) 31.2 (20e44)
Use of assistive devices, no. (%) 5 (12.8) 4 (21.1) 9 (15.5)
Total knee surgery candidates 28 (71.8) 13 (68.4) 41 (70.1)baseline outcome measures and KellgreneLawrence X-ray
grades.
OUTCOME MEASURES
Table II(a) shows the differences between the active and
placebo groups’ percent changes from baseline to the 3-
month visit for each primary outcome measure, and for total
WOMAC scores as well. Analyses of differences between
treatment groups were statistically signiﬁcant for ﬁve of
these six outcome measures: patient global, patient pain,
WOMAC stiffness, WOMAC function, and total WOMAC.
Only the WOMAC composite pain scale difference was
not signiﬁcant. The study data are also presented in Tables
II(b)e(d) as raw scores (mm), differences from baseline
(mm), and percent changes from baseline, all expressed
as the mean standard deviation.
Figure 2 shows the percent of patients in each treatment
group who experienced 50% or greater improvement in
each primary outcome measure. Three of ﬁve primary out-
come measures showed a signiﬁcant difference between
active and placebo groups, and a small percent of placebo
patients showed a 50% change in each measure. The ex-
ceptions were WOMAC stiffness (P¼ 0.08) and function
(P¼ 0.14). The total WOMAC was at least 50% improved
in 23.1% of active and 5.3% of placebo patients, but did
not reach signiﬁcance (P¼ 0.14). Twenty-one of 39 actively
Table I(b)
Comparison of baseline disease severity characteristics between
active- and placebo-treated patients. Patient global evaluation
was worse at baseline for the participants in the active group
(P¼ 0.04). No other statistically significant differences between
groups were present
Active Placebo
Outcome measures*
Patient global 51.3 41.4
Patient pain 50.9 48.1
WOMAC pain 50.6 44.9
WOMAC stiffness 58.4 53.4
WOMAC function 51.9 44.9
KellgreneLawrence X-ray grade, no. of points
1 0 0
2 0 0
3 20 10
4 19 9
*See Table II(b) for baseline means standard deviations.treated patients improved by 50% in at least one outcome
measure vs ﬁve of 19 placebo patients. Ten active and no
placebo patients improved 50% in four to six measures.
The 18 active patients who had no 50% responses did
not differ in their hours of treatment from those who did.
Valid statistical testing of these trends was not possible.
Table III shows that hours of use were similar in the two
treatment groups. The placebo patients used the device for
a mean of 656 193 h (range 310e1052), and the active
patients for 692 187 h (range 0e1019) (P¼ 0.52). The
hours of use for each group were normally distributed,
and the ShapiroeWilk W statistic was >0.90. About 60%
of each group achieved an average use of 6 h or more
per day.
The voltage amplitude that patients dialed into their de-
vices could range from 0 to 12 V. Actual mean amplitudes
were 4.7 1.1 V for the placebo-treated group and
4.1 0.98 V for the active group (P¼ 0.03). The amplitudes
were normally distributed. This small 0.6 V difference is
electronically meaningless and could not inﬂuence the out-
come differences between the two groups. The slightly
higher signal amplitudes delivered to the placebo patients
were delivered for less than 5 min after the device setup
each day.
ADVERSE DEVICE EFFECTS
A skin rash developed at the site of electrode placement
in 21.1% of placebo and 17.9% of active patients
(P> 0.05). These were usually transient and required only
local topical therapy, stopping device use for a few days,
and/or a change in the conducting gel. Previous studies
and post marketing clinical observations indicate that
most rashes are due to the conducting gel. No systemic
Table II(a)
Percent change from baseline in efficacy outcome parameters. Per-
cent differences represent differences between active and placebo
groups, with all differences favoring active over placebo
Outcome Difference P value
Patient global 50.56 0.031
Patient pain 31.20 0.038
WOMAC pain 19.85 0.110
WOMAC stiffness 25.06 0.030
WOMAC function 29.46 0.013
Total WOMAC 26.64 0.014
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Raw mean scores (mm) for active and placebo device groups
Active (N¼ 39) Placebo (N¼ 19)
Baseline 3 months Baseline 3 months
Mean Standard deviation Mean Standard deviation Mean Standard deviation Mean Standard deviation
Patient global 51.3 17.38 38.3 25.81 41.4 16.12 45.1 21.41
Patient pain 50.9 17.99 36.2 26.05 48.1 16.76 45.7 21.76
WOMAC pain 50.6 14.20 37.4 23.60 44.9 12.47 41.8 16.59
WOMAC stiffness 58.4 20.07 43.1 28.59 53.4 16.13 50.1 18.09
WOMAC function 51.9 15.98 39.9 24.59 44.9 14.87 46.6 18.31
Total WOMAC 52.2 14.90 39.6 24.25 45.6 13.32 45.9 16.81reactions occurred, and no unanticipated adverse device
effects were reported.
Discussion
Active PES treatment of these patients with moderate to
severe knee OA provided signiﬁcant and clinically meaning-
ful improvement relative to placebo in four of ﬁve primary
outcome measures, including the patient global, pain and
symptoms, and the WOMAC stiffness and function sub-
scales [Table II(a)]. The total WOMAC score, added to the
results at the request of reviewers, was also improved, as
would be expected. Only the results of the WOMAC ﬁve
question pain subscale failed to reach signiﬁcance
(P¼ 0.11); however, when 50% or more improvements
were compared, active treatment was superior for the
WOMAC pain as well, as shown in Fig. 2 (P¼ 0.03). No
systemic adverse device events appeared in this study.
The results of the WOMAC function subscale were also dis-
cordant for signiﬁcant effect between the primary measure
(P¼ 0.013) and the number of 50% improvers (P¼ 0.14),
but the latter also favored active over placebo treatment.
The inclusion of total WOMAC scores does not alter the
signiﬁcance of results, but does offer a composite of the
individual outcomes measures.
Our 58 patient study population was smaller than origi-
nally planned because an additional 42 subjects at a third
site were disqualiﬁed after many received other new treat-
ments during the study. Clinical records from this site did
not permit us to identify which patients were so treated
and to maintain them in an intent-to- treat analysis, as the
protocol stipulated. Because each site was randomized
separately, however, this exclusion did not alter the active:
placebo device ratio, permitting us to analyze the remaining
two site population in this manner. While we recognize this
exclusion as a departure from the protocol, we believe it to
be an appropriate approach to this unusual occurrence.The signiﬁcance of the results in spite of this unforeseen
reduction is explained primarily by the large effect size of
active treatment, but also by both the severity of baseline
disease and symptoms and the low response to placebo
treatment. Semiﬂexed knee X-rays showed Kellgrene
Lawrence Grade 3 changes in 52% of patients and Grade
4 changes in 48%, and WOMAC pain scores were greater
than 200 in 74% of active and 63% of placebo patients in
spite of baseline NSAID and/or analgesic therapy. Placebo
patients experienced low frequencies of 50% or greater
improvement in outcome measures in contrast to a higher
proportion of the actively treated patients. The lower than
expected patient numbers, the lower than recommended
total treatment hours in 40% of study patients, and the
relatively brief study duration probably all contribute to the
one primary and two secondary outcomes that did not reach
signiﬁcance, suggesting that even greater effectiveness
would be demonstrated in the absence of these limitations,
as suggested by another published cohort study10. PES
therapy was added to current, stable, and continuous back-
ground OA drug treatment. No ‘‘wash out’’ of OA medicines
was conducted to produce a ﬂare in baseline symptoms.
Thus the ﬁnding of increased efﬁcacy on top of background
therapy also emphasizes the clinical signiﬁcance of the
results.
These data conﬁrm and extend the results of previous
studies using the same PES signal, including a 1-month
randomized, placebo-controlled trial7, a long-term TKA de-
ferral study8,9, and clinical experience captured in a phase
IV treatment cohort10. Other investigators have also im-
proved knee OA symptoms with a different highly speciﬁc
PES signal27e29. In contrast, another recent trial using an
electronically and biophysically different pulsed electromag-
netic ﬁeld (PEMF) device failed to provide relief for 90 knee
OA patients30. These differing results indicate that the efﬁ-
cacy of PES resides in the speciﬁc properties of the electri-
cal signal generated by each device type, that the signal
must be optimized and proven in clinical trials to assureTable II(c)
Absolute difference from baseline in millimeters
Active (N¼ 39) Placebo (N¼ 19) ActiveePlacebo (N¼ 58)
Mean Standard deviation Mean Standard deviation Mean Standard deviation P value
Patient global 12.9 24.45 3.7 23.43 16.6 24.13 0.017
Patient pain 14.7 23.12 2.3 21.95 12.4 22.75 0.057
WOMAC pain 13.2 22.33 3.1 15.38 10.1 20.35 0.080
WOMAC stiffness 15.4 23.55 3.3 18.29 12.1 22.00 0.053
WOMAC function 12.0 19.22 1.7 13.48 13.7 17.58 0.007
Total WOMAC 12.5 19.34 0.3 12.43 12.8 17.42 0.004
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Percent change from baseline
Active (N¼ 39) Placebo (N¼ 19) ActiveePlacebo (N¼ 58)
Mean Standard deviation Mean Standard deviation Mean Standard deviation P value
Patient global 24.2 47.87 26.3 90.43 50.6 64.68 0.032
Patient pain 30.3 46.28 0.9 63.74 31.2 52.53 0.038
WOMAC pain 25.1 45.57 5.3 39.46 19.9 43.70 0.110
WOMAC stiffness 26.3 41.15 1.2 38.39 25.1 40.29 0.030
WOMAC function 24.2 41.71 5.3 39.31 29.5 40.95 0.013
Total WOMAC 25.6 39.05 1.1 33.42 26.7 37.34 0.014efﬁcacy, and that positive or negative treatment outcomes
obtained with one signal cannot be extrapolated to different
signals.
The mechanism of action by which this speciﬁc PES de-
vice relieves joint symptoms in human knee OA is not
known yet, but three decades of in vitro and animal re-
search provide compelling evidence for a positive local
effect on chondrocyte function through gene regulation.
In vitro studies of cartilage explants have demonstrated that
speciﬁc, pulsed electrical signals stimulate synthesis of
DNA, Type II collagen, and aggrecan, while simultaneously
inhibiting production of molecules that destroy cartilage
such as matrix metalloproteinases and interleukin-111e22.
A recent article conﬁrmed very substantial 500e800% upre-
gulation of chondrocyte Type II collagen and aggrecan
genes in response to a capacitively coupled signal22. These
changes in gene expression are mediated through intracel-
lular signal transduction cascades that increase intracellular
calcium concentration from cytoplasmic stores. These bio-
logical changes are analogous to the gene regulating ef-
fects of hormones, growth factors, and chemical ligands31.
Parallel results have been observed with speciﬁc PES of
other mesenchymal cell types, including osteoblasts and
ﬁbroblasts32e34.
In animal studies, Lippiello and coworkers measured the
physical characteristics of natural electrical ﬁelds generated
by articular cartilage and designed a device to deliver this
pulsed electrical signal to knee cartilage from surface elec-
trodes applied over the knee. In a rabbit model of OA, this
device altered repair of injured cartilage to regeneratehyaline cartilage instead of typical scar tissue and ﬁbrocar-
tilage35. This positive effect needs to be studied in humans
with acute cartilage injury. What emerges from this body of
evidence is an essential role of intrinsic electrical signaling
in cartilage health and disease and the opportunity to treat
diseases of cartilage with optimized, capacitively coupled
PES devices.
Some critics have suggested that PES devices relieve
symptoms in the same manner as TENS. This is un-
founded. In fact, TENS and PES differ in many ways.
TENS stimulates nerves; the device used in this trial does
not. Optimal pain relief from TENS requires its application
two to four times daily for a usual maximum of 40 min; lon-
ger use attenuates pain relief. The PES device is used for
6e14 h each day, and other studies show that greater use
results in greater efﬁcacy10. TENS causes rapid release
of enkephalins and endorphins; pain relief occurs in minutes
and wanes in a few hours, just as with opiates24. PES re-
quires weeks to months of treatment for optimal pain relief,
but then the effect usually persists for weeks to years after
treatment withdrawal. Tolerance develops with TENS but
not with PES.
Knee OA causes severe disability in millions of people.
Those with moderate or severe disease who fail analgesics
and/or NSAIDs have limited therapeutic options. Some
choose TKA or other types of surgery, but many are unwill-
ing or are too young, too old, or too enfeebled by co-morbid
disease to consider surgery. PES offers a safe, noninvasive
option for such patients, and may reduce the need for TKA
as well.Fig. 2. Percentage of patients improving 50% or greater in each of the primary outcome measures.
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